治疗相关与初发成人 B 细胞急性淋巴细胞白血病的比较研究。
Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia.
机构信息
Division of Hematology and Medical Oncology, Mayo Clinic, USA.
Division of Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, FL, USA.
出版信息
Br J Haematol. 2022 Feb;196(4):963-968. doi: 10.1111/bjh.17906. Epub 2021 Oct 25.
Abstract
We report a comparative analysis of patients with therapy-related acute lymphoblastic leukaemia (tr-ALL) vs de novo ALL. We identified 331 patients with B-ALL; 69 (21%) were classified as tr-ALL. The most common prior malignancies were breast (23·2%) and plasma cell disorders (20·3%). Patients with tr-ALL were older (median 63·2 vs. 46·2 years, P < 0.001), more often female (66·7% vs. 43·5%, P < 0·001), and more likely to have hypodiploid cytogenetics (18·8% vs. 5·0%, P < 0·001). In multivariable analysis, patients with tr-ALL were less likely to achieve complete remission [odds ratio (OR) = 0·16, P < 0·001] and more likely to be minimal residual disease-positive (OR = 4·86, P = 0·01) but had similar OS after diagnosis and allo-haematopoietic cell transplantation.
摘要
我们报告了治疗相关急性淋巴细胞白血病（t r - ALL）与初发急性淋巴细胞白血病（de novo ALL）患者的对比分析。我们确定了 331 例 B-ALL 患者；69 例（21%）被归类为 t r - ALL。最常见的既往恶性肿瘤为乳腺癌（23.2%）和浆细胞疾病（20.3%）。t r - ALL 患者年龄更大（中位数 63.2 岁 vs. 46.2 岁，P<0.001），女性比例更高（66.7% vs. 43.5%，P<0.001），且更可能存在亚二倍体细胞遗传学异常（18.8% vs. 5.0%，P<0.001）。多变量分析显示，t r - ALL 患者完全缓解的可能性较低（比值比[OR] = 0.16，P<0.001），微小残留病阳性的可能性较高（OR = 4.86，P=0.01），但在诊断和异体造血细胞移植后，其总生存情况无显著差异。
相似文献
1
Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia.治疗相关与初发成人 B 细胞急性淋巴细胞白血病的比较研究。
Br J Haematol. 2022 Feb;196(4):963-968. doi: 10.1111/bjh.17906. Epub 2021 Oct 25.
2
Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients.与急性淋巴细胞白血病相比，治疗相关性急性淋巴细胞白血病具有独特的临床和细胞遗传学特征，但在接受移植的患者中，其结局相当。
Haematologica. 2018 Oct;103(10):1662-1668. doi: 10.3324/haematol.2018.193599. Epub 2018 Jun 14.
3
Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation.异基因造血干细胞移植治疗急性淋巴细胞白血病：一项代表欧洲血液和骨髓移植学会白血病工作组的研究。
Br J Haematol. 2019 Sep;186(5):767-776. doi: 10.1111/bjh.15973. Epub 2019 May 22.
4
Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia working party of the European group for Blood and Marrow Transplantation.微小残留病对费城染色体阳性成人急性淋巴细胞白血病患者脐带血移植后结局的影响：代表欧洲脐带血库、脐带血委员会及欧洲血液与骨髓移植组急性白血病工作组所做的分析
Br J Haematol. 2014 Sep;166(5):749-57. doi: 10.1111/bjh.12970. Epub 2014 Jun 25.
5
Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.在接受清髓性异基因移植的成人急性淋巴细胞白血病患者中可测量残留病：来自 EBMT 急性白血病工作组的 2780 例患者的回顾性登记研究。
J Hematol Oncol. 2019 Oct 23;12(1):108. doi: 10.1186/s13045-019-0790-x.
6
Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapy-refractory or relapsed disease prior to allogeneic stem cell transplantation.在接受异基因干细胞移植前化疗耐药或复发的急性淋巴细胞白血病患者中，残留病是一个强有力的预后标志物。
Br J Haematol. 2021 Jul;194(2):403-413. doi: 10.1111/bjh.17646. Epub 2021 Jun 22.
7
Measurable Residual Disease Assessment and Allogeneic Transplantation as Consolidation Therapy in Adult Acute Lymphoblastic Leukemia in Colombia.哥伦比亚成人急性淋巴细胞白血病巩固治疗中的可测量残留病评估和异基因移植。
Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):e365-e372. doi: 10.1016/j.clml.2020.11.010. Epub 2020 Nov 14.
8
Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions.急性白血病移植后复发的分析：二次异基因造血细胞移植与供体淋巴细胞输注的比较
Exp Hematol. 2018 Jun;62:24-32. doi: 10.1016/j.exphem.2018.03.002. Epub 2018 Mar 8.
9
Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.采用供体外周血淋巴细胞对骨髓移植后复发白血病进行异基因细胞治疗。
Exp Hematol. 1995 Dec;23(14):1553-62.
10
Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia.异基因造血细胞移植的非清髓预处理治疗高危急性淋巴细胞白血病。
Haematologica. 2011 Aug;96(8):1113-20. doi: 10.3324/haematol.2011.040261. Epub 2011 Apr 20.
引用本文的文献
1
Survival outcomes in secondary and primary acute lymphoblastic leukemia: a systematic review and meta-analysis.继发性和原发性急性淋巴细胞白血病的生存结局：一项系统评价和荟萃分析。
Sci Rep. 2025 Jun 2;15(1):19282. doi: 10.1038/s41598-025-95356-5.
2
Allogeneic hematopoietic cell transplantation is equally effective in secondary acute lymphoblastic leukemia (ALL) compared to de-novo ALL-a report from the EBMT registry.与原发性急性淋巴细胞白血病（ALL）相比，异基因造血细胞移植治疗继发性急性淋巴细胞白血病（ALL）的效果相同——来自欧洲血液与骨髓移植协会（EBMT）登记处的一份报告。
Bone Marrow Transplant. 2024 Mar;59(3):387-394. doi: 10.1038/s41409-023-02192-0. Epub 2024 Jan 9.
3
Therapy-related B-lymphoblastic leukemia after multiple myeloma.多发性骨髓瘤后与治疗相关的B淋巴细胞白血病
Leuk Res Rep. 2022 Nov 1;18:100358. doi: 10.1016/j.lrr.2022.100358. eCollection 2022.
4
Therapy-related Acute Lymphoblastic Leukaemia has a Unique Genetic Profile Compared to Acute Lymphoblastic Leukaemia.与急性淋巴细胞白血病相比，治疗相关的急性淋巴细胞白血病具有独特的基因图谱。
J Cancer. 2022 Sep 11;13(12):3326-3332. doi: 10.7150/jca.76719. eCollection 2022.
5
Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma.多发性骨髓瘤治疗后与治疗相关的急性淋巴细胞白血病的独特特征和结局
Blood Cancer J. 2022 Jun 1;12(6):87. doi: 10.1038/s41408-022-00680-y.
本文引用的文献
1
Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH-based algorithm distinguishes prognostic groups and outcomes.使用基于荧光原位杂交（FISH）的算法鉴定成人费城样急性淋巴细胞白血病可区分预后分组和结局。
Blood Cancer J. 2021 Sep 21;11(9):156. doi: 10.1038/s41408-021-00538-9.
2
Impact of Novel Targeted Therapies and Cytogenetic Risk Groups on Outcome After Allogeneic Transplantation for Adult ALL.新型靶向治疗和细胞遗传学危险组对成人 ALL 异基因移植后结局的影响。
Transplant Cell Ther. 2021 Feb;27(2):165.e1-165.e11. doi: 10.1016/j.jtct.2020.10.015. Epub 2020 Dec 11.
3
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes.治疗相关性急性淋巴细胞白血病是一种具有不良遗传学特征和临床结局的独特实体。
Blood Adv. 2019 Dec 23;3(24):4228-4237. doi: 10.1182/bloodadvances.2019000925.
4
Therapy-related acute lymphoblastic leukemia: Where do we stand with regards to its definition and characterization?治疗相关性急性淋巴细胞白血病：在其定义和特征方面，我们处于什么位置？
Blood Rev. 2019 Sep;37:100584. doi: 10.1016/j.blre.2019.06.001. Epub 2019 Jun 19.
5
Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma.多发性骨髓瘤后继发急性淋巴细胞白血病：一种克隆无关的第二原发恶性肿瘤。
Leukemia. 2019 Jan;33(1):266-270. doi: 10.1038/s41375-018-0213-y. Epub 2018 Jul 19.
6
Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients.与急性淋巴细胞白血病相比，治疗相关性急性淋巴细胞白血病具有独特的临床和细胞遗传学特征，但在接受移植的患者中，其结局相当。
Haematologica. 2018 Oct;103(10):1662-1668. doi: 10.3324/haematol.2018.193599. Epub 2018 Jun 14.
7
Second primary acute lymphoblastic leukemia in adults: a SEER analysis of incidence and outcomes.成人第二原发性急性淋巴细胞白血病：SEER 分析发病率和结局。
Cancer Med. 2018 Feb;7(2):499-507. doi: 10.1002/cam4.1266. Epub 2017 Dec 28.
8
Secondary acute lymphoblastic leukemia is a distinct clinical entity with prognostic significance.继发性急性淋巴细胞白血病是一种具有明确临床意义和预后价值的独特疾病实体。
Blood Cancer J. 2017 Sep 8;7(9):e605. doi: 10.1038/bcj.2017.81.
9
Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial.对CALGB（联盟）100104研究的更新分析：评估来那度胺与安慰剂在多发性骨髓瘤单次自体干细胞移植后维持治疗中的疗效比较——一项随机、双盲、3期试验
Lancet Haematol. 2017 Sep;4(9):e431-e442. doi: 10.1016/S2352-3026(17)30140-0. Epub 2017 Aug 17.
10
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial.来那度胺治疗背景下的第二原发性恶性肿瘤：对纳入骨髓瘤XI试验的2732例骨髓瘤患者的分析。
Blood Cancer J. 2016 Dec 9;6(12):e506. doi: 10.1038/bcj.2016.114.
Zotero 插件